文献速递心力衰竭与心肌病心律失常

修饰mRNA治疗恢复桥粒胶蛋白2缺陷致心律失常性右室心肌病小鼠模型的心功能

Modified mRNA Treatment Restores Cardiac Function in Desmocollin-2-Deficient Mouse Models of Arrhythmogenic Right Ventricular Cardiomyopathy.
PubMed 文献 · Circulation · 2025-04-11

本研究在一consanguineous中国家系中通过全外显子测序发现DSC2新变异导致常染色体隐性ARVC,并构建Dsc2敲入和敲除小鼠模型。Dsc2缺陷小鼠出现右室扩张和功能障碍,转录组分析发现Myl7下调最显著,AAV9恢复Myl7可挽救心功能;Dsc2 mRNA经心内或经冠状动脉注射可使心脏大小和功能正常化,单次给药疗效持续2至3个月。

要点

  • DSC2功能缺失通过下调Myl7导致ARVC及扩张型心肌病右室收缩功能障碍。
  • Dsc2 mRNA递送可恢复Dsc2缺陷小鼠的心脏大小和功能。
  • 单次mRNA治疗疗效持续2至3个月后下降。

核心结论

  • DSC2功能缺失通过下调Myl7导致ARVC和伴右室收缩功能障碍的扩张型心肌病。
  • Dsc2 mRNA治疗在ARVC和横向主动脉缩窄模型中显示显著治疗潜力。

研究设计与样本

  • 研究通过全外显子测序在一个近亲结婚的中国家系中鉴定出导致常染色体隐性ARVC的新DSC2序列变异。
  • 构建Dsc2序列变异敲入和组成性敲除小鼠模型,采用超声心动图和组织学分析。
  • 进行转录组和生化分析探索ARVC机制。
  • 在Dsc2敲除小鼠中评估经心内或经冠状动脉注射递送的Dsc2 mRNA的治疗效果。
  • 在横向主动脉缩窄小鼠模型中检查Dsc2 mRNA对非遗传性右室收缩功能障碍的作用。

主要发现

  • Dsc2缺陷小鼠表现出右室扩张和功能障碍,模拟人类疾病。
  • 转录组分析确定Myl7为Dsc2缺陷小鼠右室中下调最显著的基因,通过AAV9恢复Myl7可挽救心脏功能。
  • Dsc2 mRNA递送(无论是否用脂质纳米颗粒包裹)使Dsc2缺陷小鼠的心脏大小和功能正常化。
  • 在非遗传性扩张型心肌病患者和横向主动脉缩窄小鼠中观察到DSC2和MLC2a表达降低。
  • 单次mRNA剂量提供持续2至3个月的治疗效果,之后下降。

临床怎么用

  • Dsc2 mRNA治疗在ARVC和横向主动脉缩窄模型中显示治疗潜力,为未来临床应用提供基础。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Arrhythmogenic right ventricular cardiomyopathy (ARVC) is an inherited heart disease characterized by irregular rhythms and right ventricular dysplasia. Sequence variations in desmosomal protein-encoding genes are linked to ARVC development. Effective treatments for ARVC are lacking. Whereas mRNA-based therapies have shown efficacy in humans, their therapeutic potential for inherited cardiomyopathies remains unclear. METHODS: Whole-exome sequencing identified a novel DSC2 sequence variation causing autosomal recessive ARVC in a Chinese family with consanguineous marriage. Mouse models with Dsc2 sequence variation knock-in and constitutive knock-out were generated and analyzed using echocardiography and histology. Transcriptomic and biochemical analyses were conducted to explore ARVC mechanisms. Dsc2 mRNA delivered by intracardiac or transcoronary injection was assessed as a treatment for ARVC in Dsc2 knock-out mice. In addition, effects of Dsc2 mRNA were examined in a transverse aortic constriction mouse model with noninherited right ventricular systolic dysfunction. RESULTS: Dsc2-deficient mice exhibited right ventricular dilation and dysfunction, mimicking human disease. Transcriptomic analysis identified Myl7 as the most downregulated gene in the right ventricles of Dsc2-deficient mice, and its restoration by adeno-associated virus 9 rescued heart function. Dsc2 mRNA delivery, with or without lipid nanoparticle encapsulation, normalized heart size and function in Dsc2-deficient mice. Reduced DSC2 and MLC2a expression was also noted in patients with noninherited dilated cardiomyopathy and in mice with transverse aortic constriction. A single dose of mRNA provided therapeutic effects lasting 2 to 3 months before declining. CONCLUSIONS: Our study reveals novel mechanisms of ARVC caused by DSC2 loss of function, supported by human and mouse data. Loss of Myl7 contributes to reduced cardiac contractility in ARVC and dilated cardiomyopathy with right ventricular systolic dysfunction. Dsc2 mRNA treatment demonstrated significant therapeutic potential in ARVC and transverse aortic constriction models, providing a basis for future clinical applications.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Zou Y, Lu J, Lian Z, et al. Modified mRNA Treatment Restores Cardiac Function in Desmocollin-2-Deficient Mouse Models of Arrhythmogenic Right Ventricular Cardiomyopathy. Circulation. 2025. PMID: 40211944. doi:10.1161/CIRCULATIONAHA.124.072340

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。